HEBER
CITY, Utah, July 25,
2024 /PRNewswire/ -- Renew Biotechnologies, a
leading biotech company dedicated to pioneering NGS-based
diagnostic solutions, appoints Steven
Abbott as Chief Operating Officer (COO). Mr. Abbott brings
extensive experience in genomics and biotechnology operations to
lead Wasatch BioLabs, a core Renew Biotechnologies subsidiary, from
its current research and development phase into full-scale
commercial operations.
"We are excited to have Steven
Abbott join our executive team at this pivotal point in our
development," said Chad Pollard,
Co-Founder and CEO of Renew Biotechnologies. "We are building a
20,000 sqft high-throughput clinical laboratory at Wasatch Biolabs
to transition to full-scale clinical services. Steven's molecular
diagnostics expertise and operational experience will be crucial in
this shift. We are confident his leadership will drive the
successful development and launch of our innovative
sequencing-based diagnostic tools."
Wasatch Biolabs' proprietary nanopore-based sequencing
technologies are designed to serve researchers, clinical service
providers, and biotech companies, including other Renew portfolio
companies. These companies operate across diverse therapeutic areas
such as neurodegenerative disease and women's health.
"I am pleased to join Renew Biotechnologies to advance Wasatch
Biolabs and other portfolio companies," commented Mr. Abbott. "The
unique capabilities of Wasatch Biolabs' novel sequencing
technologies present an incredible opportunity to enhance
diagnostics across multiple fields. I look forward to working with
the Renew team to bring these innovative solutions to market and
make real impacts on patient care."
A Proven Leader in Biotechnology and Genomic
Operations
Steven Abbott's career spans over
15 years in the biotechnology and life sciences industries. Most
recently, he served as Vice President of Lab Operations at Flagship
Biosciences, Inc., where he significantly enhanced lab productivity
and operational efficiency. Prior, Mr. Abbott held leadership
positions at Q² Solutions, including Director of Genomics Business
Development and Director of Global Genomics Lab Operations, where
he oversaw global NGS operations and expanded capabilities into new
markets.
At Renew Biotechnologies, Steven
Abbott will be pivotal in transitioning Wasatch BioLabs into
a fully operational high-throughput commercial lab. His extensive
experience in lab operations, business development, and strategic
planning will drive this initiative forward. Under Mr. Abbott's
leadership, Wasatch Biolabs is poised to make significant strides
in commercializing innovative diagnostic technologies.
Through collaboration with healthcare and industry leaders,
Renew Biotechnologies aims to equip researchers and providers with
genomic and epigenomic tools that enhance decision-making and
deliver breakthroughs that improve patient outcomes and transform
healthcare. Steven Abbott will be an
impactful leader, ensuring that Renew Biotechnologies and its
subsidiaries continue leading the way in clinical diagnostics.
About Renew Biotechnologies
Renew Biotechnologies is at the forefront of revolutionizing
clinical diagnostics by developing and launching a series of
specialized biotechnology companies. By collaborating with
healthcare and industry leaders, Renew Biotechnologies aims to
equip researchers and providers with genomic and epigenomic tools
that enhance decision-making and improve patient outcomes. Each
subsidiary is dedicated to transforming healthcare, one
breakthrough at a time.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/renew-biotechnologies-welcomes-steven-abbott-as-chief-operating-officer-to-lead-wasatch-biolabs-transition-to-commercial-operations-302206716.html
SOURCE Renew Biotechnologies